Navigation Links
MAP Pharmaceuticals Provides Update on LEVADEX® Program
Date:4/12/2012

MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the potential acute treatment of migraine in adults.

  • The Company submitted a request to the U.S. Food and Drug Administration (FDA) for a meeting to discuss the Complete Response letter received on March 26, 2012. The Company announced that the FDA has scheduled a meeting with the Company, to occur in the second quarter.
  • On April 3, 2012, the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 8,148,377, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine While Minimizing Side Effect Profile." This new patent, which expires in 2028, is the third in a series of patents issued to the Company relating to the pharmacokinetics of LEVADEX. The new patent results from the Company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic profiles of DHE that result in rapid efficacy while minimizing side effects that are typically seen with other migraine drugs.  

"We are pleased that the FDA has scheduled a meeting with us to discuss the issues contained in the Complete Response letter for LEVADEX," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "We continue to work closely together with our partner, Allergan, as we seek to resolve the issues in the Complete Response letter as quickly as possible."

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the poten
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)...  Four financial reasons to reduce pressure ulcers ... by Leaf Healthcare, Inc . According ... (AHRQ), pressure ulcers cost the US healthcare ... addition to direct treatment related costs, pressure ulcers ... impact hospital performance metrics. On top of the ...
(Date:9/3/2015)... Corporation (NASDAQ: OMER ) today announced that it ... and its subsidiary, Par Sterile Products, LLC, (collectively "Par") ... New Jersey and in the ... Delaware . The lawsuits were filed under the ... U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856, which relate ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... of the "Investigation Report on China,s Levothyroxine ... Thyroid hormones (TH) have the greatest ... younger ones. Without thyroid hormones mainly promote the ... organs, even the growth hormone (GH) of pipuitary ...
Breaking Medicine Technology:Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4Investigation Report on China's Levothyroxine Market, 2010-2019 2
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ... the real estate investment landscape by connecting accredited and institutional investors to real ... financing products designed to meet demand from both investors and sponsoring real ...
(Date:9/3/2015)... ... September 03, 2015 , ... Girl’s Night Out to benefit Core Compassion ... Farm, 6205 Kate Road in Monroe, North Carolina. The event food will ... social function, Kate Clyde’s offers off-premise catering and event services from casual to elegant. ...
(Date:9/3/2015)... WA (PRWEB) , ... September ... ... of Washington, a leading provider of comprehensive eating disorder treatment for adults ... announced today that Ileana Calinoiu, MD has joined the medical treatment team. ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor ... may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated ... caused by HPV infections, which have a high rate of success in treatment and ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic ... virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this ... Scripts and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies ...
Breaking Medicine News(10 mins):Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2
... ... ... ... ...
... - Researchers from The University of Texas M. D. ... to measure the severity of symptoms that can complicate ... chronic graft-versus-host disease (cGVHD), and was presented with supporting ... Meeting. cGVHD - a chronic disease that ...
... Radio ... This study appears in Plastic and Reconstructive Surgery, the offical medical journal of the American ... ... procedures in the world for excess fat removal - and while its relative safety and ...
... with type 1 disease from daily injections, expert predicts, , ... treatment with a hormone linked to weight loss seems to ... raising the prospect of a landmark new treatment for some ... as leptin, will work against type 1 diabetes. But if ...
... apt to enhance verbal skills, experts say, , MONDAY, ... their infants in front of supposedly brain-enhancing DVDs in ... be accomplishing nothing, new research shows. , What,s more, ... DVDs at an earlier age actually had lower levels ...
... ... ... ... ...
Cached Medicine News:Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 2Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 3Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 4Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 5Health News:M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms 2Health News:M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms 3Health News:New Study Tunes Into Latest Lipo Technique 2Health News:Hormone Outperforms Insulin in Diabetic Mice 2Health News:Watching Special Videos May Not Make Kids Brainier 2Health News:Watching Special Videos May Not Make Kids Brainier 3Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 2Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 3Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 4
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
Immersion Oil, 21,000 cs...
Immersion Oil, 1,250 cs...
... standard - the ones to compare with, the ... led in the development and standardization of immersion ... record: , When the FDA set general purpose ... Diagnostics in the 1970's, Cargille Immersion Oils were ...
Medicine Products: